Request Demo
Last update 16 Jul 2026
Dupilumab Biosimilar (Qilu Pharmaceutical)
Last update 16 Jul 2026
Overview
Basic Info
Drug Type Biosimilar, Monoclonal antibody |
Synonyms Dupilumab Biosimilar (Qilu Pharmaceutical Co., Ltd.), 度普利尤单抗生物类似药（齐鲁制药有限公司）, QL-2108 + [1] |
Target |
Action inhibitors |
Mechanism IL-13 inhibitors(Interleukin-13 inhibitors), IL-4 inhibitors(Interleukin-4 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Sequence Code 9909199H
The sequence is quoted from: *****
Sequence Code 9931072L
The sequence is quoted from: *****
Related
2
Clinical Trials associated with Dupilumab Biosimilar (Qilu Pharmaceutical)NCT06884891
A Multicenter Randomized, Double-blinded, Parallel, Positive-controlled, Phase Ⅲ Comparative Study to Evaluate the Efficacy and Safety of QL2108 to Dupixent® in Adult Subjects With Moderate-to-Severe Atopic Dermatitis.
NCT06614907
A Randomized, Double-blinded, Parallel, Single-dose, PhaseⅠComparative Study to Evaluate the Pharmacokinetics and Safety of QL2108 to Dupixent® in Healthy Chinese Adult Subjects
100 Clinical Results associated with Dupilumab Biosimilar (Qilu Pharmaceutical)
Login to view more data
100 Translational Medicine associated with Dupilumab Biosimilar (Qilu Pharmaceutical)
Login to view more data
100 Patents (Medical) associated with Dupilumab Biosimilar (Qilu Pharmaceutical)
Login to view more data
100 Deals associated with Dupilumab Biosimilar (Qilu Pharmaceutical)
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Moderate Atopic Dermatitis | Phase 3 | China | 02 Apr 2025 | |
| Severe Atopic Dermatitis | Phase 3 | China | 02 Apr 2025 | |
| Dermatitis, Atopic | Phase 3 | - | 01 Apr 2025 | |
| Asthma | IND Approval | China | 20 Jun 2024 | |
| prurigo nodularis | IND Approval | China | 20 Jun 2024 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free